Research location
Terni
Umbria, Italy
Advertisement
Research activity in Terni
Umbria, ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 13 trials and 13 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Terni
13 linked trials · page 1 of 1A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06790693 · 2025-04-09 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's DiseaseNCT04777331 · 2021-05-05 · 1 site observation
ACTIVE_NOT_RECRUITING
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT03850795 · 2021-03-15 · 1 site observation
TERMINATED
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic FailureNCT04095793 · 2019-09-19 · 1 site observation
TERMINATED
A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.NCT03840200 · 2019-06-12 · 1 site observation
COMPLETED
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast CancerNCT02402712 · 2015-05-06 · 1 site observation
COMPLETED
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerNCT01966471 · 2014-01-31 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast CancerNCT01565083 · 2012-04-01 · 1 site observation
COMPLETED
A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast CancerNCT01358877 · 2011-11-08 · 1 site observation
COMPLETED
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast CancerNCT01401166 · 2011-10-01 · 1 site observation
COMPLETED
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor TherapyNCT01437566 · 2011-10-01 · 1 site observation
COMPLETED
COX-2 Inhibitor Study In Patients With Rheumatoid ArthritisNCT00113308 · 2005-06-01 · 1 site observation
COMPLETED
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 DiabetesNCT00359112 · 2004-02-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.